Centivax is a South San Francisco–based biotechnology company (founded in 2019) on a mission to create post-pathogen immunity using a proprietary computational immune-engineering platform. Today, it’s leading the development of broad-spectrum vaccines—including a universal flu vaccine now in preclinical tests in animals and organoids—and is expanding into antibody therapies targeting pathogens like HIV, RSV, and multi-drug-resistant bacteria, as well as antivenoms and future-focused disease interventions.